E
14.50
-0.18 (-1.23%)
前收盘价格 | 14.68 |
收盘价格 | 15.01 |
成交量 | 121,374 |
平均成交量 (3个月) | 288,160 |
市值 | 377,746,752 |
预期市盈率 (P/E Forward) | 41.32 |
价格/销量 (P/S) | 11.51 |
股市价格/股市净资产 (P/B) | 19.04 |
52周波幅 | |
利润日期 | 18 Mar 2025 |
营业毛利率 | -9.80% |
营业利益率 (TTM) | 8.96% |
稀释每股收益 (EPS TTM) | -0.150 |
季度收入增长率 (YOY) | 59.30% |
总债务/股东权益 (D/E MRQ) | 122.79% |
流动比率 (MRQ) | 2.06 |
营业现金流 (OCF TTM) | 2.12 M |
杠杆自由现金流 (LFCF TTM) | -18.78 M |
资产报酬率 (ROA TTM) | -2.53% |
股东权益报酬率 (ROE TTM) | -19.16% |
市场趋势
短期 | 中期 | ||
行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
股票 | Eton Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.6
分析师共识 | 4.0 |
内部交易活动 | NA |
价格波动 | -0.5 |
技术平均移动指标 | -1.0 |
技术振荡指标 | 4.0 |
平均 | 1.63 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. |
|
部门 | Healthcare |
行业 | Drug Manufacturers - Specialty & Generic |
投资方式 | Small Growth |
内部持股比例 | 5.57% |
机构持股比例 | 48.62% |
52周波幅 | ||
目标价格波幅 | ||
高 | 33.00 (HC Wainwright & Co., 127.59%) | 购买 |
中 | 26.00 (79.31%) | |
低 | 24.00 (B. Riley Securities, 65.52%) | 购买 |
平均值 | 27.67 (90.83%) | |
总计 | 3 购买 | |
平均价格@调整类型 | 14.88 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
B. Riley Securities | 19 Mar 2025 | 24.00 (65.52%) | 购买 | 14.88 |
Craig-Hallum | 19 Mar 2025 | 26.00 (79.31%) | 购买 | 14.88 |
HC Wainwright & Co. | 19 Mar 2025 | 33.00 (127.59%) | 购买 | 14.88 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合